Literature DB >> 1765892

Treatment issues for opioid-dependent women during the perinatal period.

L P Finnegan1.   

Abstract

Opioid dependence has been studied with regard to its effects on the woman, the fetus, and the child for the past three decades, and it continues to be a serious problem that must be recognized and addressed by the health care delivery system in order to provide optimal medical care. The use of pharmacotherapy, such as methadone maintenance treatment (MMT), is only one of a variety of treatment modalities to provide optimal services for opioid-dependent women. The complete schema for treating opioid dependence in the perinatal period is complex and intense, but MMT serves multiple purposes. Primarily, it removes the addicted woman from the drug-seeking environment, eliminates the necessary illicit behavior, and prevents the peaks and valleys in the maternal heroin level that may occur throughout the day. In addition, maternal nutrition is usually improved and MMT patients become amenable to prenatal care and psychosocial rehabilitation. It is evident from the findings of numerous studies that when the physical, psychological, and socioeconomic issues of pregnant opioid-dependent women and their children are coupled with MMT, the potential physical and behavioral effects of psychoactive drugs on the mother, the fetus, the newborn, and the child may be markedly reduced.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765892     DOI: 10.1080/02791072.1991.10472236

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  26 in total

Review 1.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Concentrations of methadone in breast milk and plasma in the immediate perinatal period.

Authors:  Lauren M Jansson; Robin E Choo; Cheryl Harrow; Martha Velez; Jennifer R Schroeder; Ross Lowe; Marilyn A Huestis
Journal:  J Hum Lact       Date:  2007-05       Impact factor: 2.219

3.  Pregnancy and race/ethnicity as predictors of motivation for drug treatment.

Authors:  Mary M Mitchell; S Geoff Severtson; William W Latimer
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

4.  Clinical correlates of prescription opioid analgesic use in pregnancy.

Authors:  Megan V Smith; Darce Costello; Kimberly A Yonkers
Journal:  Matern Child Health J       Date:  2015-03

5.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

Review 6.  The management of opioid dependence during pregnancy in rural and remote settings.

Authors:  Naana Afua Jumah; Lisa Graves; Meldon Kahan
Journal:  CMAJ       Date:  2014-10-06       Impact factor: 8.262

7.  The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

Authors:  Hendrée E Jones; Lauren M Jansson; Kevin E O'Grady; Karol Kaltenbach
Journal:  Neurotoxicol Teratol       Date:  2013 Sep-Oct       Impact factor: 3.763

Review 8.  Evaluation and management of opioid dependence in pregnancy.

Authors:  Eliza M Park; Samantha Meltzer-Brody; Joji Suzuki
Journal:  Psychosomatics       Date:  2012-08-14       Impact factor: 2.386

9.  Comparison of characteristics of opioid-using pregnant women in rural and urban settings.

Authors:  Sarah H Heil; Stacey C Sigmon; Hendree E Jones; Michael Wagner
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.